Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma

Zhou, Xin; Sun, Chao; Wang, Jing; Mao, Jingjue; Guo, Hongwei

doi:10.3816/clml.2010.n.023

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence of severe pulmonary complications after the third bortezomib cycle has been described by Boyer et al [ 5 ]. Another case published by Zhou et al [ 6 ] relates to a patient developing acute respiratory insufficiency several hours after the first injection of bortezomib, rapidly leading to death. Our observation is the first to describe such a late onset of pulmonary symptoms after starting chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia

Vandeix

Favard²,

Pichon³

et al. 2012

Case Reports in Pulmonology

View full text Add to dashboard Cite

Introduction. Bortezomib is a proteasome inhibitor indicated for the treatment of multiple myeloma patients. The most frequent side effects are gastrointestinal and neurological. Serious pulmonary complications have been described rarely. Observation. This case involves a 74-year-old man suffering from IgG Kappa myeloma treated with bortezomib, melphalan, and dexamethasone. After administering chemotherapy, the patient developed an acute respiratory distress syndrome (ARDS). A surgical pulmonary biopsy proved the existence of bronchiolitis obliterans organizing pneumonia (BOOP) lesions. Systemic corticotherapy led to a rapid improvement in the patient's condition. Conclusion. This is the first reported histologically confirmed case of bortezomid-induced BOOP. Faced with severe respiratory symptoms in the absence of other etiologies, complications due to bortezomid treatment should be evoked and corticotherapy considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia

Vandeix

Favard²,

Pichon³

et al. 2012

Case Reports in Pulmonology

View full text Add to dashboard Cite

show abstract

“…A Pub-Med search of ''bortezomib'' AND (''pulmonary'' OR ''lung'') yielded numerous cases or case series describing the characteristics of lung injury potentially caused by bortezomib. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] On review of all reported cases, BILD has been previously described in patients with multiple myeloma, acute myeloid leukemia, non-Hodgkin's lymphoma, and Waldenstrom's macroglobulinemia. This is the first reported case of BILD in a patient with amyloidosis.…”

Section: Discussionmentioning

confidence: 99%

Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report

Balsman¹

2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

Bortezomib was the first antineoplastic proteasome inhibitor and is currently indicated for the treatment of hematologic malignancies including multiple myeloma and mantle cell lymphoma. This report describes a 57-year-old patient with light chain (primary) amyloidosis receiving weekly subcutaneous bortezomib injections who presented with recurrent hypoxemia and interstitial pneumonitis. Following the failure of conventional therapy, the patient responded rapidly to high-dose intravenous methylprednisolone. Oxygen therapy was able to be weaned off within three days and he was able to be discharged to home in stable condition, with follow-up computed tomography showing improving lung lesions. Bortezomib is known to rarely cause acute lung injury, but this complication has not been previously described in the setting of amyloidosis. Clinicians should be aware of potentially severe pulmonary adverse effects in all patients treated with bortezomib.

show abstract

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

Camus

2010

Pulmonary Involvement in Patients With Hematological Malignancies

View full text Add to dashboard Cite

Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma

Cited by 5 publications

References 20 publications

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia

Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

Contact Info

Product

Resources

About